	US 11,806,319 B2
	Pharmaceutical composition comprising a cannabinoid
Jitinder Wilkhu, Cambridge (GB); and Johan Bender, Berg en Dal (NL)
Assigned to GW Research Limited, Cambridge (GB)
Appl. No. 16/959,350
Filed by GW Research Limited, Cambridge (GB)
PCT Filed Jan. 2, 2019, PCT No. PCT/GB2019/050007 § 371(c)(1), (2) Date Jun. 30, 2020, PCT Pub. No. WO2019/135075, PCT Pub. Date Jul. 11, 2019.
Claims priority of application No. 1800072 (GB), filed on Jan. 3, 2018.
Prior Publication US 2021/0059960 A1, Mar. 4, 2021
Int. Cl. A61K 31/05 (2006.01); A61K 31/352 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61K 47/22 (2006.01); A61K 47/34 (2017.01)

CPC A61K 31/05 (2013.01) [A61K 31/352 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/22 (2013.01); A61K 47/34 (2013.01)]

18 Claims

1. An oral pharmaceutical formulation comprising:

cannabidiol (CBD) or cannabidivarin (CBDV);

poloxamer 124 or poloxamer 188, or a mixture thereof; and

diacetin, propylene glycol, triacetin, monoacetin, propylene glycol diacetate, triethyl citrate, or a mixture thereof;

wherein the oral pharmaceutical formulation is contained in a container,

wherein the container is a blister pack, and

wherein the blister pack comprises a cavity forming film comprising aluminium and a lidding material comprising aluminium.